PMID: 22565535May 9, 2012Paper

Emerging therapies for residual risk

Reviews in Cardiovascular Medicine
Sanjay MehraAssad Movahed

Abstract

The role of statins in reducing the risk of coronary artery disease is well established. The use of statins in patients at high risk for cardiovascular disease has reduced the incidence of major clinical events by 25% to 40%. However, despite aggressive statin therapy and the achievement of target low-density lipoprotein cholesterol levels, the residual risk of cardiovascular events remains high. This review investigates emerging therapies to target the residual risk of cardiovascular events with concurrent statin therapy.

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Journal of Cardiopulmonary Rehabilitation and Prevention
Ewa Dembowski, Michael H Davidson
© 2021 Meta ULC. All rights reserved